Pfizer PFE announced that it has settled its litigation against Teva
Pharmaceuticals, USA Inc., relating to Pfizer's patent covering the use
of Viagra® to treat erectile dysfunction (sildenafil…
Pfizer Inc. announced that it has settled its litigation against Teva
Pharmaceuticals, USA TEVA, relating to Pfizer's patent covering the use
of Viagra® to treat erectile dysfunction (sildenafil citrate 25, 50, and
100 mg tablets), which expires in April 2020 (including pediatric
exclusivity). As a result of the settlement, Teva will be allowed to
launch a generic version of Viagra® in the United States on December 11,
2017, or earlier under certain circumstances. Teva will pay Pfizer a
royalty for a license to produce its generic version. The terms of the
settlement agreement are otherwise confidential. Teva has received
tentative approval from the U.S. Food and Drug Administration (FDA) for
its generic version of Viagra®.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in